ENXTPA:ABNX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

€27.5m

Last Updated

2021/06/21 21:31 UTC

Data Sources

Company Financials +

Executive Summary

ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has ABIONYX Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ABNX is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: ABNX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of French stocks.


Market Performance


7 Day Return

-3.4%

ABNX

-2.3%

FR Biotechs

-0.2%

FR Market


1 Year Return

21.7%

ABNX

28.7%

FR Biotechs

34.2%

FR Market

Return vs Industry: ABNX matched the French Biotechs industry which returned 28.6% over the past year.

Return vs Market: ABNX underperformed the French Market which returned 34.2% over the past year.


Shareholder returns

ABNXIndustryMarket
7 Day-3.4%-2.3%-0.2%
30 Day-14.5%0.3%3.6%
90 Day18.6%-7.5%11.0%
1 Year21.7%21.7%28.7%28.7%38.3%34.2%
3 Year-44.3%-44.3%-15.1%-15.1%34.3%23.2%
5 Year-84.4%-84.4%-41.2%-41.3%94.0%65.9%

Long-Term Price Volatility Vs. Market

How volatile is ABIONYX Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is ABIONYX Pharma undervalued compared to its fair value and its price relative to the market?

12.48x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ABNX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ABNX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ABNX is unprofitable, so we can't compare its PE Ratio to the French Biotechs industry average.

PE vs Market: ABNX is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: ABNX is unprofitable, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: ABNX is good value based on its PB Ratio (3.8x) compared to the FR Biotechs industry average (4.5x).


Future Growth

How is ABIONYX Pharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-24.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABNX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ABNX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ABNX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if ABNX's revenue is forecast to grow faster than the French market.

High Growth Revenue: Insufficient data to determine if ABNX's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ABNX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has ABIONYX Pharma performed over the past 5 years?

53.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ABNX is currently unprofitable.

Growing Profit Margin: ABNX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ABNX is unprofitable, but has reduced losses over the past 5 years at a rate of 53.9% per year.

Accelerating Growth: Unable to compare ABNX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ABNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (21.8%).


Return on Equity

High ROE: ABNX has a negative Return on Equity (-28.5%), as it is currently unprofitable.


Financial Health

How is ABIONYX Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: ABNX's short term assets (€10.1M) exceed its short term liabilities (€3.5M).

Long Term Liabilities: ABNX's short term assets (€10.1M) exceed its long term liabilities (€117.0K).


Debt to Equity History and Analysis

Debt Level: ABNX's debt to equity ratio (16.5%) is considered satisfactory.

Reducing Debt: ABNX's debt to equity ratio has reduced from 1026.6% to 16.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ABNX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ABNX has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 16.3% each year.


Dividend

What is ABIONYX Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ABNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ABNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ABNX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABNX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ABNX's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

Cyrille Tupin (44 yo)

1.75yrs

Tenure

€4,641,579

Compensation

Mr. Cyrille Tupin, CPA is Chief Executive Officer, General Manager and Director at ABIONYX Pharma SA since September 6, 2019. Mr. Tupin served as the Chief Financial and Administrative Officer at ABIONYX ...


CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether Cyrille's total compensation is reasonable compared to companies of similar size in the French market.

Compensation vs Earnings: Insufficient data to compare Cyrille's compensation with company performance.


Leadership Team

Experienced Management: ABNX's management team is considered experienced (4.4 years average tenure).


Board Members

Experienced Board: ABNX's board of directors are considered experienced (6.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.3%.


Top Shareholders

Company Information

ABIONYX Pharma SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ABIONYX Pharma SA
  • Ticker: ABNX
  • Exchange: ENXTPA
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €27.504m
  • Shares outstanding: 24.56m
  • Website: https://abionyx.com

Number of Employees


Location

  • ABIONYX Pharma SA
  • 33-43 av. Georges Pompidou – Bât. D2
  • Labege
  • Midi-Pyrénées
  • 31130
  • France

Listings


Biography

ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portf...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/21 21:31
End of Day Share Price2021/06/21 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.